Dr Maki-Petaja won a poster prize (125 Euros) at the Artery Conference in Guimaraes, Portugal in October 2018. The poster depicted results from the HYPAZ study, which was a collaborative effort between EMIT and Oncology, led by Dr Joseph Cheriyan (co-PI) for experimental techniques to measure cardiovascular pharmacodynamics and Prof Duncan Jodrell, as Chief Investigator for the oncological aspects. The aim of the study was to gain a better understanding to the underlying mechanisms of hypertension caused by a commonly used cancer therapy. We conducted a clinical trial in oncology patients receiving vascular endothelial growth factor (VEGF) inhibitor, Pazopanib. Using sophisticated tools to measure changes in capillaries, resistance vessels and large vessels in-vivo, our results demonstrate some novel mechanisms by which VEGF inhibition could result in hypertension. We are currently preparing the manuscript and hope to report the full results soon.